Migraine affects over one billion people globally and is a significant cause of disability, particularly during prime working years. Psychiatric comorbidities such as depression, anxiety, and PTSD are associated with migraines, leading to increased health care resource utilization and chronic migraine. Since 2018, eight novel-mechanism calcitonin gene-related peptide (CGRP) antagonists have been FDA-approved for migraine treatment, highlighting the need for education on their use. Surveys indicate that many individuals with migraine have unmet treatment needs, and psychiatric pharmacists play a crucial role in addressing these through advanced decision-making strategies and patient-specific care. This session aims to help psychiatric pharmacists understand the risks, benefits, and treatment strategies for implementing CGRP antagonists in the treatment of migraines.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Mikiko Y. Takeda, PharmD, MS, BCACP, FAES
Associate Professor, University of New Mexico College of Pharmacy
Mikiko Takeda is an Associate Professor at the University of New Mexico College of Pharmacy, where she leads instruction on neurological diseases, including headache disorders, chronic pain, complementary and alternative medicine, and biostatistics. As a licensed pharmacist in both Japan and the United States, Dr. Takeda brings a unique set of experiences that are broadly applicable to patient care and research. Specifically, she is a pharmacist clinician with prescriptive authority, allowing her to provide patient care in pain management (e.g., chronic non-cancer pain, migraine headaches) and epilepsy. Recently, Dr. Takeda has also begun offering medication management services for patients with cerebral cavernous malformation who experience headaches and epilepsy. Her research at the University of New Mexico (UNM) Pain Center and the Alcohol and Substance Abuse Program (ASAP) focuses on innovative strategies for the safe administration of medication-assisted therapy (e.g., naloxone) to combat opioid use disorder (OUD). At the UNM Pain Center, the team developed a co-prescribing model for opioids and naloxone as a universal precaution. This model has since been integrated into New Mexico's safe opioid prescribing legislation. Additionally, the team has published research demonstrating that widespread naloxone distribution among individuals with OUD significantly increases overdose reversals, ultimately reducing opioid-related deaths.
Learning Objectives
- Identify potential risks and/or benefits of using calcitonin gene-related peptide antagonists for the treatment of migraine based on available data and clinical experience.
- Design a treatment regimen for migraine when given a patient case scenario.
- Modify migraine treatment regimens to align with individual patient needs, preferences, and treatment goals.
Continuing Education Credit and Disclosures
Activity Dates: 10/03/2025 - 10/03/2028
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-25-032-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.